JPMorgan Chase & Co. Cuts BioNTech (NASDAQ:BNTX) Price Target to $120.00

BioNTech (NASDAQ:BNTX) had its target price trimmed by JPMorgan Chase & Co. from $121.00 to $120.00 in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other research firms have also commented on BNTX. Wells Fargo & Company set a $150.00 price target on shares of BioNTech and gave the company an “overweight” rating in a research report on Tuesday, August 5th. Morgan Stanley reduced their price target on BioNTech from $133.00 to $131.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Bank of America dropped their price objective on BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $136.00 target price on shares of BioNTech in a research note on Monday, September 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Tuesday, October 14th. Ten equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $133.96.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $105.66 on Thursday. BioNTech has a 52 week low of $81.20 and a 52 week high of $129.27. The business’s 50 day moving average price is $103.20 and its 200 day moving average price is $104.59. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The firm has a market cap of $25.40 billion, a P/E ratio of -66.04 and a beta of 1.45.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The business had revenue of $306.46 million during the quarter, compared to analysts’ expectations of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. BioNTech’s revenue for the quarter was up 102.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that BioNTech will post -3.88 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Banque Cantonale Vaudoise purchased a new position in BioNTech during the first quarter worth about $36,000. Financial Consulate Inc. purchased a new position in BioNTech in the third quarter worth approximately $36,000. LRI Investments LLC grew its position in BioNTech by 234.6% in the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock worth $47,000 after acquiring an additional 312 shares during the period. Tower Research Capital LLC TRC increased its stake in BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after acquiring an additional 305 shares during the last quarter. Finally, Hantz Financial Services Inc. raised its position in BioNTech by 472.0% in the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock valued at $61,000 after purchasing an additional 472 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.